Services General Administration and Coordination Department, Government of Sindh

Spruce Power Announces Record Net Income in Second Quarter 2023 Earnings Results

Retrieved on: 
Thursday, August 10, 2023
Alternative Energy, Energy, Event, Share repurchase, Services General Administration and Coordination Department, Government of Sindh, Telephone, Spruce, Wind, LOI, New York Stock Exchange, EBITDA, Acquisition, Spruce Finance, Depreciation, Growth, Security (finance), PPA, Hand, Conference, NYSE, Cryptocurrency, Holding company, Commercial property, Bank

Revenues totaled $22.8 million for the second quarter of 2023, compared to $18.1 million for the first quarter of 2023.

Key Points: 
  • Revenues totaled $22.8 million for the second quarter of 2023, compared to $18.1 million for the first quarter of 2023.
  • Net income attributable to stockholders was $3.1 million for the second quarter of 2023, compared to a net loss attributable to stockholders of $19.4 million for the first quarter of 2023.
  • Adjusted EBITDA and proceeds from investment in lease agreement, in the aggregate, was $13.8 million for the second quarter of 2023, compared to $5.7 million for the first quarter of 2023.
  • The Spruce management team will host a conference call to discuss its second quarter 2023 financial results today at 2:30 p.m. Mountain Time.

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Well, Tissue, ESCAPE, Research and development, HBF, Biotechnology, Allele, Gene editing, SCD, Clinical trial, Cancer, SMART Process Acceleration Development Environment, G&A, CD34, BCL11A, AATD, Fetal hemoglobin, CGMP, Patient, Investment, Security (finance), Administration, Cas9, Hematology, Sickle cell disease, Liver, Growth, Hospital, Trial of the century, LNP, LNP Media Group, R, Services General Administration and Coordination Department, Government of Sindh, Treatment, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Television, Beam

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2023 financial results and provided an update on its clinical and pipeline progress.

Key Points: 
  • Beam continues to expect initiation of current good manufacturing practice compliant operations at its North Carolina manufacturing facility in late 2023.
  • Research & Development (R&D) Expenses: R&D expenses were $97.6 million for the second quarter of 2023, compared to $74.6 million for the second quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $24.7 million for the second quarter of 2023, compared to $24.1 million for the second quarter of 2022.
  • Net Loss: Net loss was $82.8 million for the second quarter of 2023, or $1.08 per share, compared to $72.0 million for the second quarter of 2022, or $1.02 per share.

Spruce Power Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023
Environment, Residential Building & Real Estate, Alternative Energy, Green Technology, Energy, Construction & Property, SG, Event, Share repurchase, Services General Administration and Coordination Department, Government of Sindh, Telephone, Spruce, History, Wind, Kilowatt-hour, EBITDA, Acquisition, Depreciation, Growth, Weather, Conference, NYSE, Common, Cryptocurrency, Bank, Video game

Spruce Power Holding Corporation (NYSE: SPRU) (“Spruce” or the “Company”), a leading owner and operator of distributed solar energy assets across the United States, today reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • Spruce Power Holding Corporation (NYSE: SPRU) (“Spruce” or the “Company”), a leading owner and operator of distributed solar energy assets across the United States, today reported financial results for the quarter ended March 31, 2023.
  • With these underlying initiatives largely in the rear-view mirror, we look forward to the quarters ahead when we expect results to more fully reflect Spruce Power's stand-alone residential solar business and the positive financial benefits of the Spruce Power 4 acquisition.”
    Revenues totaled $18.1 million for the first quarter of 2023 and the same amount for the fourth quarter of 2022.
  • SG&A expense dropped to $15.7 million for the first quarter of 2023, compared to $28.6 million for the fourth quarter of 2022.
  • The Spruce Power management team will host a conference call to discuss its first quarter 2023 financial results today at 2:30 p.m. Mountain Time.

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
Well, GMP, Tissue, ESCAPE, Research and development, Drug development, Stargardt disease, Hematology, Gene targeting, Biotechnology, SCD, Clinical trial, Bone marrow, Cancer, G&A, Patient, Eye, Science, AATD, Investment, Security (finance), Administration, DSM-IV codes, Sickle cell disease, Liver, R, LNP, LNP Media Group, Services General Administration and Coordination Department, Government of Sindh, Society, Vaccine, Pharmaceutical industry, Medical imaging, Stargardt, Beam

CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2023 financial results and provided an update on its BEACON clinical trial and pipeline progress.

Key Points: 
  • Beam expects to fully enroll the sentinel cohort in 2023.
  • Beam expects to initiate current good manufacturing practice compliant operations at its North Carolina manufacturing facility in late 2023.
  • Research & Development (R&D) Expenses: R&D expenses were $99.6 million for the first quarter of 2023, compared to $65.4 million for the first quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $23.5 million for the first quarter of 2023, compared to $19.2 million for the first quarter of 2022.

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 23, 2023
Haematopoiesis, GMP, Research and development, Siddhartha Mukherjee, Bone marrow, Clinical trial, Passive treatment system, Coronavirus Scientific Advisory Board, Cmax, Doctor of Philosophy, HSCT, Trial of the century, Acute myeloid leukemia, MRD, CAR, AML, Good manufacturing practice, CD33, Patient, Investment, CGMP, Transplant, Administration, Blood, AUC, Biology, TANDEM, HSC, R, Services General Administration and Coordination Department, Government of Sindh, IND, Acute promyelocytic leukemia, Satellite navigation device, Nursing, Vaccine, Dentistry, Cryptocurrency, G&A, MD, Gemtuzumab ozogamicin

In December 2022, Vor Bio announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.

Key Points: 
  • In December 2022, Vor Bio announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.
  • The Company intends to evaluate VCAR33ALLO in combination with trem-cel as a Treatment System, aiming at prolonged remissions or cures following transplant.
  • General & Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2022 were $7.7 million, compared to $5.6 million for the fourth quarter of 2021, and for the year ended December 31, 2022, were $28.9 million, compared to $21.5 million for the year ended December 31, 2021.
  • Net Loss: Net loss for the fourth quarter of 2022 was $23.9 million, compared to $18.3 million for the fourth quarter of 2021, and for the year ended December 31, 2022, was $92.1 million, compared to $68.9 million for the year ended December 31, 2021.

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, CABE, Cancer, Services General Administration and Coordination Department, Government of Sindh, DSM-IV codes, Tada, Research, Research and development, Investment, CBQT-FM, Patient, R, Commencement (album), Liver, CBE, Pondok Cabe Airport, Hematology, AATD, Cytosine, Security (finance), Nature Biotechnology, C. E. T. Warren, ESCAPE, Administration, G&A, Pharmaceutical industry, Cryptocurrency, Beam

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reaffirmed its anticipated upcoming milestones across the company’s hematology, immunology-oncology, and genetic disease portfolios and reported fourth quarter and full year 2022 financial results.

Key Points: 
  • North Carolina Manufacturing Facility Open and Operational, Expected to Commence cGMP Operations in Late 2023
    Ended Fourth Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities
    CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reaffirmed its anticipated upcoming milestones across the company’s hematology, immunology-oncology, and genetic disease portfolios and reported fourth quarter and full year 2022 financial results.
  • Research & Development (R&D) Expenses: R&D expenses were $86.3 million for the fourth quarter of 2022 and $311.6 million for the full year ended December 31, 2022, compared to $96.8 million for the fourth quarter of 2021 and $387.1 million for the full year ended December 31, 2021.
  • General & Administrative (G&A) Expenses: G&A expenses were $22.7 million for the fourth quarter of 2022 and $87.8 million for the full year ended December 31, 2022, compared to $17.8 million for the fourth quarter of 2021 and $57.2 million for the full year ended December 31, 2021.
  • Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2022, will enable the company to fund its anticipated operating expenses and capital expenditure requirements at least into 2025.

Optinose Announces CEO Transition and Business Update

Retrieved on: 
Tuesday, January 31, 2023
GAAP, Diagnosis, ENT, Ear, Military reserve force, Lieutenant colonel, Walter Reed Army Institute of Research, Medication, Nose, Ethicon Inc., Drug discovery, MPH, Policy, New Drug Application, Polyp (medicine), Patient, University, Army of the United States, FDA, Health, OPTN, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Growth, Sinusitis, Johnson & Johnson, Services General Administration and Coordination Department, Government of Sindh, Textbook, Research, Public health, Management, Pharmaceutical industry, Medical device, MD

In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose.

Key Points: 
  • In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose.
  • During Mr. Miller’s nearly 13 years as CEO, the Company experienced significant growth.
  • Dr. Mahmoud, the Company’s President and Chief Operating Officer since 2010, will succeed Mr. Miller as the new CEO of Optinose and as a Board member, effective immediately.
  • “Ramy’s leadership and accomplishments, deep industry experience, and medical background make him ideally suited to succeed Peter as CEO of Optinose,” said Joseph C. Scodari, Chairman of the Optinose Board of Directors.

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Retrieved on: 
Thursday, August 11, 2022
Stem cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acute myeloid leukemia, U.S. Securities and Exchange Commission, Risk, Forward-looking statement, GLOBE, R, Standard of care, HSPC, Private Securities Litigation Reform Act, Growth, Clinical trial, Investment, CGMP, Haematopoietic system, IND, Security (finance), Gene editing, Services General Administration and Coordination Department, Government of Sindh, AML, Blood, Public expenditure, Lymphatic system, Facility, Patient, Engineering, Company, Research and development, Phenotype, Health, Immunotherapy, CD33, HCT, Capital expenditure, Time, Administration, Food, Medical imaging, Pharmaceutical industry, Vaccine, Q4, Gemtuzumab ozogamicin, G&A

In-house manufacturing facility in Cambridge, MA operational in Q4 2022

Key Points: 
  • In-house manufacturing facility in Cambridge, MA operational in Q4 2022
    CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2022, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2022 were $15.3 million, compared to $13.0 million for the second quarter of 2021.
  • General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2022 were $6.5 million, compared to $5.4 million for the second quarter of 2021.
  • Net Loss: Net loss for the second quarter of 2022 was $21.7 million, compared to $18.4 million for the second quarter of 2021.

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Thursday, August 11, 2022
Fulcrum, GlaxoSmithKline, Patient registration, Services General Administration and Coordination Department, Government of Sindh, Investor relations, GLOBE, Growth, Conference call, IND, Research, Merck, General counsel, Patient, Therapy, D, HBF, Merck & Co., G&A, Â, Webcast, Nasdaq, Thalassemia, Conference, Investigational New Drug, REACH, Pharmaceutical industry, Cryptocurrency, Management, Video game, SCD, FSHD

In the second quarter, we achieved major milestones in both of our clinical programs, said Bryan Stuart, Chief Executive Officer of Fulcrum Therapeutics.

Key Points: 
  • In the second quarter, we achieved major milestones in both of our clinical programs, said Bryan Stuart, Chief Executive Officer of Fulcrum Therapeutics.
  • Collaboration Revenue: Collaboration revenue was $1.9 million for the second quarter of 2022, as compared to $4.4 million for the second quarter of 2021.
  • G&A Expenses: G&A expenses were $11.1 million for the second quarter of 2022, as compared to $6.7 million for the second quarter of 2021.
  • ET to discuss its second quarter 2022 recent business highlights and financial results.

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 16, 2022
Acute myeloid leukemia, GBM, Lymphoid leukemia, R, Food, U.S. Securities and Exchange Commission, Annual report, AML, CELU, Biology, Insurance, Cash, Trastuzumab, Form 10-K, Services General Administration and Coordination Department, Government of Sindh, Private Securities Litigation Reform Act, Treatment, Clinical trial, Society, Stomach, FDA, Securities Act of 1933, Pembrolizumab, Food and Drug Administration, IND, Securities Exchange Act of 1934, Industry, Chimeric antigen receptor T cell, General officer, NK, Drug discovery, 3D ultrasound, Communication, Terminology, SG, Acute leukemia, Risk, Drug Quality and Security Act, ASH, Security (finance), CD16, Administration, CAR, Fast Track, SEC, Cancer, Research and development, Interleukin, CD19, GLOBE, Pharmaceutical industry, Vaccine, Instituto de Biologia Molecular e Celular

Total Revenues: Total revenues were $5.9 million for the first quarter of 2022, compared to $2.7 million for the first quarter of 2021.

Key Points: 
  • Total Revenues: Total revenues were $5.9 million for the first quarter of 2022, compared to $2.7 million for the first quarter of 2021.
  • Research & Development (R&D) Expenses: R&D expenses were $21.7 million for the first quarter of 2022, compared to $17.0 million for the first quarter of 2021.
  • Selling, General & Administrative (SG&A) Expenses: SG&A expenses were $16.5 million for the first quarter of 2022, compared to $7.6 million for the first quarter of 2021.
  • Net loss: Net loss for the first quarter of 2022 was $62.9 million, or $(0.48) per share for both basic and diluted shares.